Med anledning av bolagets kvartalsrapport 3 för 2024/2025, bjuder Hamlet BioPharma in till en livesänd digital pressträff torsdagen den 22 maj, 2025, klockan 12.00. Bolaget…
Som tidigare rapporterats har Hamlet BioPharma uppnått banbrytande forskningsresultat om Alpha1H, bolagets läkemedelskandidat mot urinblåsecancer. I samarbete med Lunds universitet har en ny studie (publicerad…
As previously reported, Hamlet BioPharma has achieved a groundbreaking scientific discovery related to Alpha1H, the company’s lead drug candidate for the treatment of bladder cancer….
Hamlet BioPharma utvald att presentera framgångsrika prekliniska och kliniska data för Alpha1H vid AACR 2025 vid American Association for Cancer Research (AACR) Annual Meeting 2025…
As previously announced Hamlet BioPharma invites you to our monthly investors’ meeting to be held on the 23rd of April 2025, at 12:00. Please click…
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces the publication of new scientific advances important for identifying…
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces the publication of new scientific advances important for the…
Hamlet BioPharma’s extensive patent portfolio comprises 147 granted patents and 33 pending cases. Strategy regarding intellectual property rights, follow up and extension of filed cases…
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces that Hamlet BioPharma’s drug candidate Alpha1H has shown potent…